Market Cap 76.45M
Revenue (ttm) 0.00
Net Income (ttm) -22.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 458,700
Avg Vol 929,570
Day's Range N/A - N/A
Shares Out 60.67M
Stochastic %K 16%
Beta 0.30
Analysts Sell
Price Target $14.00

Company Profile

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Industry: Biotechnology
Sector: Healthcare
Phone: 312 416 8592
Address:
444 West Lake Street, Suite 1700, Chicago, United States
lookingaroundhere
lookingaroundhere Apr. 24 at 12:49 PM
$MAIA According to the letter to shareholders 2026 the key takeaways: Strong momentum in clinical trials of lead molecule, ateganosine, as a treatment for non-small cell lung cancer. Phase 3 Thio - 104 full approval trial underway with high probability of technical success on both interim and full analysis. Phase 2 Thio-101 expansion (Part C) nearing completion with potential for accelerated approval. Unprecedented interim measures of efficacy. FDA fast track designation as a third-line therapy for NSCLC. Potential breakthrough therapy with substantial commercial opportunity in a ~$50 billion global immunotherapy market.
1 · Reply
My_Lai_1968
My_Lai_1968 Apr. 24 at 1:05 AM
$MAIA This stock has been charting for a long, long time to plummet swiftly into the dark, murky waters (a.k.a. "Sub-$1"), where its odds of resurfacing are slim and none. Watch closely as throngs of cantankerous, petrified shareholders--- reeling from the continual threats by their nagging wives that the families hard earned money is being squandered and pissed away --- begin to quickly dump their shares in a desperate attempt to salvage a few nickels and dimes of their original investment. The gloom is real, the doom is deadly. Act now to save a pittance of your child's college money and even faster for totally cutting off your wives undeserved jewelry gifts. She's no doubt "boinking" the electric repair man as you are slaving away at work for her. You will need to scrape by just to find a spot to sleep under the nearest bridge.
1 · Reply
Arbguy8888
Arbguy8888 Apr. 23 at 7:52 PM
$MAIA Not sure whether I should be concerned about the planned single arm THIO-101 part D. It is not all that difficult to switch at this point should they receive negative feedback.
1 · Reply
Arbguy8888
Arbguy8888 Apr. 22 at 11:10 PM
$MAIA Any thoughts on the failure of $REPL approval? Seems to avoid the single arm pitfall, and there are some issues with their specific treatment injecting specific lesions, as well as the heterogeneity of the patient population wrt prior interventions. $MAIA does not seem to have those issues https://download.open.fda.gov/crl/CRL_BLA125827_20260410.pdf
0 · Reply
JordiWild
JordiWild Apr. 21 at 11:35 PM
0 · Reply
claybridge
claybridge Apr. 21 at 3:02 PM
$MAIA in at $1.36 for a swing. Inverse head and shoulders in play.
1 · Reply
LabPsycho
LabPsycho Apr. 20 at 9:17 PM
$MAIA — A glimpse into a speculative AI-designed world, based in part on my ideas and images in the posts below, where a PD-L1:6-Thio-2′-deoxyguanosine antibody–drug conjugate is activated in situ by light—imagining a future of higher precision, greater efficacy, and fewer side effects.
2 · Reply
LabPsycho
LabPsycho Apr. 20 at 5:46 PM
$MAIA According to my calculations, recent volume plus price movements increase probabilty of predicted $1.49 near term from 80% (at the time, see below) to now 92%.
0 · Reply
vividC
vividC Apr. 20 at 4:02 PM
$MAIA Updated path to $10/share now requires: ~$800M valuation. We need something like: Strong Phase 2 ORR/DOR dataset or large partnership / royalty deal or clear FDA accelerated approval path
3 · Reply
GISBlaster98
GISBlaster98 Apr. 20 at 3:10 PM
$MAIA Our time will come….
0 · Reply
Latest News on MAIA
MAIA Biotechnology Announces $1.51 Million Private Placement

Dec 16, 2025, 4:15 PM EST - 4 months ago

MAIA Biotechnology Announces $1.51 Million Private Placement


MAIA Biotechnology Announces $736,600 Private Placement

Oct 13, 2025, 4:20 PM EDT - 6 months ago

MAIA Biotechnology Announces $736,600 Private Placement


MAIA Biotechnology Announces $2.25 Million Private Placement

Sep 29, 2025, 4:30 PM EDT - 7 months ago

MAIA Biotechnology Announces $2.25 Million Private Placement


MAIA Biotechnology to Present at BIO International Convention 2025

Jun 10, 2025, 8:46 AM EDT - 11 months ago

MAIA Biotechnology to Present at BIO International Convention 2025


MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025, 4:05 PM EDT - 1 year ago

MAIA Biotechnology Announces $1.08 Million Private Placement


MAIA Biotechnology Announces Private Placement of $2,715,000

Feb 18, 2025, 3:44 PM EST - 1 year ago

MAIA Biotechnology Announces Private Placement of $2,715,000


MAIA Biotechnology to Present at Biotech Showcase 2025

Jan 10, 2025, 9:45 AM EST - 1 year ago

MAIA Biotechnology to Present at Biotech Showcase 2025


MAIA Biotechnology Transcript: AGM 2024

May 23, 2024, 6:00 PM EDT - 2 years ago

MAIA Biotechnology Transcript: AGM 2024


lookingaroundhere
lookingaroundhere Apr. 24 at 12:49 PM
$MAIA According to the letter to shareholders 2026 the key takeaways: Strong momentum in clinical trials of lead molecule, ateganosine, as a treatment for non-small cell lung cancer. Phase 3 Thio - 104 full approval trial underway with high probability of technical success on both interim and full analysis. Phase 2 Thio-101 expansion (Part C) nearing completion with potential for accelerated approval. Unprecedented interim measures of efficacy. FDA fast track designation as a third-line therapy for NSCLC. Potential breakthrough therapy with substantial commercial opportunity in a ~$50 billion global immunotherapy market.
1 · Reply
My_Lai_1968
My_Lai_1968 Apr. 24 at 1:05 AM
$MAIA This stock has been charting for a long, long time to plummet swiftly into the dark, murky waters (a.k.a. "Sub-$1"), where its odds of resurfacing are slim and none. Watch closely as throngs of cantankerous, petrified shareholders--- reeling from the continual threats by their nagging wives that the families hard earned money is being squandered and pissed away --- begin to quickly dump their shares in a desperate attempt to salvage a few nickels and dimes of their original investment. The gloom is real, the doom is deadly. Act now to save a pittance of your child's college money and even faster for totally cutting off your wives undeserved jewelry gifts. She's no doubt "boinking" the electric repair man as you are slaving away at work for her. You will need to scrape by just to find a spot to sleep under the nearest bridge.
1 · Reply
Arbguy8888
Arbguy8888 Apr. 23 at 7:52 PM
$MAIA Not sure whether I should be concerned about the planned single arm THIO-101 part D. It is not all that difficult to switch at this point should they receive negative feedback.
1 · Reply
Arbguy8888
Arbguy8888 Apr. 22 at 11:10 PM
$MAIA Any thoughts on the failure of $REPL approval? Seems to avoid the single arm pitfall, and there are some issues with their specific treatment injecting specific lesions, as well as the heterogeneity of the patient population wrt prior interventions. $MAIA does not seem to have those issues https://download.open.fda.gov/crl/CRL_BLA125827_20260410.pdf
0 · Reply
JordiWild
JordiWild Apr. 21 at 11:35 PM
0 · Reply
claybridge
claybridge Apr. 21 at 3:02 PM
$MAIA in at $1.36 for a swing. Inverse head and shoulders in play.
1 · Reply
LabPsycho
LabPsycho Apr. 20 at 9:17 PM
$MAIA — A glimpse into a speculative AI-designed world, based in part on my ideas and images in the posts below, where a PD-L1:6-Thio-2′-deoxyguanosine antibody–drug conjugate is activated in situ by light—imagining a future of higher precision, greater efficacy, and fewer side effects.
2 · Reply
LabPsycho
LabPsycho Apr. 20 at 5:46 PM
$MAIA According to my calculations, recent volume plus price movements increase probabilty of predicted $1.49 near term from 80% (at the time, see below) to now 92%.
0 · Reply
vividC
vividC Apr. 20 at 4:02 PM
$MAIA Updated path to $10/share now requires: ~$800M valuation. We need something like: Strong Phase 2 ORR/DOR dataset or large partnership / royalty deal or clear FDA accelerated approval path
3 · Reply
GISBlaster98
GISBlaster98 Apr. 20 at 3:10 PM
$MAIA Our time will come….
0 · Reply
LabPsycho
LabPsycho Apr. 19 at 12:05 AM
$MAIA May as well give this a shot - posted on "X" - animated gif: Hypothetical PD-L1:6-Thio-2'deoxy-guanosine Antibody Drug Conjugate created by photoactivation. Perhaps some Visionaries at @MAIABiotech , @Roche or @Regeneron will "See the Light!" Could possibly be done by Concurrent Infusion. Increasing efficacy? https://x.com/LabPsych0/status/2045651182627004881
0 · Reply
LabPsycho
LabPsycho Apr. 17 at 2:34 PM
$MAIA @Biotech_Pharma_Investor They wanted $30M but seemingly got $33M . I still get a bit of a too over the top vibe from the CEO, but he is getting things done. And starting now a Phase 2 in USA is some more nice window dressing. I wish they would use some of my Antibody-THIO ADC ideas / graphics posted below over the past several months to try to get some big $$$ from one of MAIA's existing collaborators Roche or Regeneron
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 17 at 1:54 PM
$MAIA I missed the $30M raise. Time to revisit this one
0 · Reply
LabPsycho
LabPsycho Apr. 17 at 1:47 PM
$MAIA May be a long shot but I think it is worth a short for MAIA to apply to the NIH for a Supplemental Application now that they have announced Phase 2 in USA. https://grants.nih.gov/funding/funding-categories/supplemental-funding
0 · Reply
LabPsycho
LabPsycho Apr. 17 at 1:18 AM
$MAIA @168_swingit Great point. Or maybe now that they've raised cash they could go back to the NIH with a supplemental Grant application requesting more money with matching funds that they have.
0 · Reply
DiamondDog33
DiamondDog33 Apr. 17 at 12:41 AM
$MAIA 1 SITE IN US ??? CMON LMAO
1 · Reply
168_swingit
168_swingit Apr. 16 at 9:24 PM
$MAIA Hidden in the news is the 2.3M NIH grant that they can now use to jumpstart the US phase 3 study.
1 · Reply
Find_the_Cure
Find_the_Cure Apr. 16 at 8:26 PM
$MAIA looks good early and then fizzled out like an Alka Seltzer
0 · Reply
MoneyHelix
MoneyHelix Apr. 16 at 5:08 PM
$MAIA Insanely dumb price movement for such fantastic news. MAIA strategy is brilliant. They started Phase 3 first to collect more DCR and ORR data. Now they are starting Phase 2D in the US with even more data to justify Phase 2D expansion. This is their definitive step towards Accelerated Approval. It's just a waiting game now 🥂
1 · Reply
Zenlama
Zenlama Apr. 16 at 3:54 PM
$MAIA Always expect the "Sell on the News" effect. Just a temporary blip.
0 · Reply
mfritz89
mfritz89 Apr. 16 at 3:48 PM
$MAIA https://ir.maiabiotech.com/news-events/press-releases/detail/173/maia-biotechnology-activates-first-u-s-site-for-ongoing
1 · Reply
focafoca99
focafoca99 Apr. 16 at 3:47 PM
$MAIA activated the first U.S. clinical site in its Phase 2 expansion trial for advanced non-small cell lung cancer.
0 · Reply